Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103701 · ClinicalTrials.gov registry record · Phase 1
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00103701: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT00103701 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103701, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec).
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-11 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
What the finished NCT00103701 record still lists
NCT00103701 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT00103701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00103701 about?
NCT00103701 is a clinical study titled "BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia". The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesyl...
What is the current status of trial NCT00103701?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-11. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00103701?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00103701?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia